[ Inside the business ]

BIO stock analysis

BIO · Bio-Rad Laboratories, Inc.

Laboratory analytical instruments. Growing 1%. Loses 2¢ on every dollar.

Nothing unusual in its latest filings.

The future, in 7 questions

Priced in: 1.5× sales in 5 yrs. Evidence: sales +1% · loss growing.

01 What's priced in?1.5× sales in 5 yrs
Sales now$2.6B
Needed in 5 yrs$3.9B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +1%, steady
No customer over 10%
Prepaid $61MSales +1%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Loss growing: −2¢ per $1
'21'22'23'24'25−2¢
Before running costs: 56% → 52%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −3.4%/yrDebt $1.2B
07 What could break it?1 to watch
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +1%, −0%, then +1% vs. a year ago.

What could go wrong

Few warning signs.

It has moved 1.0× the market. In the 2022 rate shock it fell 45% while the market fell 24%. Debt is covered by cash.

Speculative check

Not classified.

Not Self-funding because of: operating loss.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

2¢ loss.

49¢ to make what it sells, 54¢ on research and overhead, nothing left over. Revenue $2.6B in the last 12 months.

Its market

0.6× the economy.

The government expects its industry, navigational, measuring, electromedical, and control instruments manufacturing, to grow 1.1% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 46¢ of each $1 of profit.

Competitive advantage

0 of 10 years.

Returns beat its 8.9% cost of capital in 0 of the last 10 years. Gross margin went from 55% to 52%.

Future bets

10% on research.

$266M a year on R&D. $139M on equipment and buildings.

All figures from Bio-Rad Laboratories, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.